drugset / Trial / NCT06265688
First In Human Study of CX-2051 in Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.
Timeline
- Start
- 2024-04-02
- Primary completion
- 2027-11-30
- Completion
- 2029-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | CX-2051 | Unknown | — | — |